Rezolute Inc
Research Rezolute Inc (RZLT) on Bullrun: market cap USD 482.42M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerRZLT
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 482.42M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 81.49M
- Free cash flow-USD 73.48M
Valuation Snapshot
latest market cap is USD 482.42M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 74.40M | -USD 77.15M | n/a | -0.98 | USD 94.11M | USD 1.29M | USD 162.13M |
| FY2024 | USD 0 | -USD 68.46M | -USD 63.44M | n/a | -1.33 | USD 70.40M | USD 1.93M | USD 121.00M |
| FY2023 | n/a | -USD 51.79M | -USD 44.63M | n/a | -1.01 | USD 16.04M | USD 2.51M | USD 116.17M |
| FY2022 | n/a | -USD 41.06M | n/a | n/a | -2.32 | USD 150.41M | USD 188.00K | USD 149.47M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 482.42M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 225.49M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 296.62M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 39.23M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 76.23M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 74.36M | n/a | n/a | n/a |
About Rezolute Inc
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Rezolute Inc's market cap?
Rezolute Inc's market capitalization is USD 482.42M.
What does Rezolute Inc do?
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017.